Dual-track pathway of bladder carcinogenesis: Practical implications

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 6, 2006, Pages 844-852

  Spiess, Philippe E ^a   Czerniak, Bogdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER PAPILLOMA; BLADDER WALL; CANCER GRADING; CANCER INVASION; CLONE; HISTOPATHOLOGY; HUMAN; HYPERPLASIA; METASTASIS; PRECANCER; REVIEW; SOLID TUMOR; BLADDER TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; HUMANS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33745027017     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Dinney CP, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell. 2004;6:111-116.
3. Heney NM, Proppe K, Prout CR Jr, Griffin PP, Shipley WU. Invasive bladder cancer: tumor configuration, lymphatic invasion, and survival. J Urol. 1990;130:895-897.
4. El-Boulkany MN, Mokhtar NM, Ghoneim MA, Hussein MH. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer. 1981;48:2643-2648.
5. Johnson DE, Schoenwald MB, Ayala AC, Miller LS. Squamous cell carcinoma of the bladder. J Urol 1976;115:542-544.
6. El-Boulkany MN, Ghoneim MA, Mansour MA. Carcinoma of the bilharzial bladder in Egypt. Br J Urol. 1972;44:561-570.
7. Zerbib M, Bouchot O. Le carcinoma epidermoide de vessie. Prog Urol. 2002;12:1115-1120.
8. Colt JS, Baris D, Stewart P, et al. Occupation and bladder cancer risk in a population-based case-control study in New Hampshire. Causes Control. 2004;15:759.
9. Ugnat AM, Luo W, Semenciw R, Mao Y. Occupational exposure to chemical and petrochemical industries and bladder cancer risk in four western Canadian provinces. Chronic Dis. Can. 2004;25:7.
10. Gazdar AF, Czerniak B. Filling the void: urinary markers for bladder cancer risk and diagnosis. J Natl Cancer Inst. 2001;93:413-415.
11. Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. JAMA. 1974;227:281-286.
12. Czerniak B, Herz F. Molecular biology of common genito-urinary tumors. In: Koss LG, ed. Diagnostic Cytology of the Urinary Tract With Histopathologic and Clinical Correlation. Philadelphia, Pa: Lippincott-Raven; 1995:345-364.
13. Cordon-Cardo C, Sheinfeld J, Dalbagni C. Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol. 1995;13:319-327.
14. Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 1982;300:149-152.
15. Czerniak B, Cohen G, Deitch D, et al. Concurrent mutations of coding and regulatory sequences of the Ha-rasgene in urinary bladder carcinomas. Hum Pathol. 1992;23:1199-1204.
16. Takahashi R, Hashimoto T, Xu HJ, et al. The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci U S A. 1991;88:5257-5261.
17. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22:1014-1024.
18. Mark L, Jones P. Presence and location of TP53 mutations determines patterns of CDKN2A/ARF pathway in bladder cancer. Cancer Res. 1998;58:5348-5353.
19. Munro NP, Knowles MA. Fibroblast growth factors and their receptors in transitional cell carcinoma. J Urol. 2003;169:675-682.
20. Kim J, Tuziak T, Hu L, et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest. 2005;85:532-549.
21. Morimoto Y, Ozaki T, Ouchida M, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003;98:2245-2250.
22. Streit S, Bange J, Fichtner A, Ihrler S, Issing W, Ullrich A. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer. 2004;111:213-217.
23. Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FCFR4 Arg(388) allele. Cancer Res. 2002;62:840-847.
24. Popov Z, Gil-Diez-De-Medina S, Ravery V, et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol. 2004;22:93-101.
25. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cis-platinum based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62:309-317.
26. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003;46:S85-104.
27. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Res 2005;11:4415-4429.
28. Modlich O, Prisack HB, Pitschke C, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 2004;10:3410-3421.
29. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003;163:505-516.
30. Perkins AS, Stern DF. Molecular biology of cancer: oncogenes. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practices of Oncology. 5th ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1997:79-119.
31. Heim S, Mitelman F. Cancer Cytogenetics. 2nd ed. New York, NY: Wiley-Liss Inc; 1995.
32. Sen S, Zhou H, Zhang RD, et al. Amplification/overexpression of mitotic kinase gene in human bladder cancer. JNCI. 2002;94:1320-1329.
33. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623-627.
34. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A. 1998;95:13692-13697.
35. Schaefer DI, Livanos EM, White AE, Tlsty TD. Multiple mechanisms of N-(phosphonoacetyl)-L-aspartate drug resistance in SV40-infected precrisis human fibroblasts. Cancer Res. 1993;53:4946-4951.
36. Bergers E, Baak JP, van Diest PJ, et al. Prognostic value of DNA ploidy using flow cytometry in 1301 breast cancer patients: results of the prospective Multicenter Morphometric Mammary Carcinoma Project. Mod Pathol. 1997;10:762-768.
37. Joensuu H, Alanen K, Falkmer UG, et al. Effect of DNA ploidy classification on prognosis in breast cancer. Int J Cancer. 1992;52:701-706.
38. Koss LG, Czerniak B, Herz F, Wersto R. Flow cytometric measurements of DNA and other cellular components in human tumors: a critical appraisal. Hum Pathol. 1989;20:528-548.
39. Risques RA, Moreno V, Marcuello E, et al. Redefining the significance of aneuploidy in the prognostic assessment of colorectal cancer. Lab Invest. 2001;81:307-315.
40. Russo A, Bazan V, Migliavacca M, et al. DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridonale (GDIM) prospective study. Cancer. 2001;92:294-302.
41. Riley RS, Mahin EJ, Ross W. DNA ploidy and cell cycle analysis. In: Riley RS, Ross W, eds. Clinical Applications of Flow Cytometry. 1st ed. New York, NY: Igaku-Shoin; 1993:251-322.
42. Danque PO, Chen HB, Patil J, et al. Image analysis versus flow cytometry for DNA ploidy quantitation of solid tumors: a comparison of six methods of sample preparation. Mod Pathol. 1993;6:270-275.
43. Francisco L, Wang W, Chan CS. Type 1 protein phosphatase acts in opposition to IpL1 protein kinase in regulating yeast chromosome segregation. Mol Cell Biol. 1994;14:4731-4740.
44. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell. 1995;81:95-105.
45. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy, and transformation. Nature Genet. 1998;20:189-193.
46. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase in oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17:3052-3065.
47. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 2002;62:6973-6980.
48. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999;59:3512-3517.
49. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 2001;20:1973-1980.
50. Cheng J, Huang H, Zhang ZT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res. 2002;62:4157-4163.
51. Watanabe T, Shinohara N, Sazawa A, et al. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther. 2000;7:1575-1580.
52. Tuzlak T, Jeong J, Majewski T, et al. High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis. Lab Invest. 2005;85:689-701.
53. Czerniak B, Chaturvedi V, Li L, et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene. 1999;18:1185-1196.
54. Czerniak B, Li L, Chaturvedi V, et al. Genetic modeling of human urinary bladder carcinogenesis. Genes Chromosomes Cancer. 2000;27:392-402.
55. Kram A, Li L, Zhang RD, et al. Mapping and genome sequence analysis of chromosome 5 regions involved in bladder cancer progression. Lab Invest. 2001;81:1039-1048.
56. Yoon DS, Li L, Zhang RD, et al. Genetic mapping and DNA sequence- based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease. Oncogene. 2001;20:5005-5014.
57. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol. 2004;46:170-176.
58. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency, and DNA ploidy. J Urol. 2001;165:1124-1128.
59. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first follow-up cystoscopy and subsequent recurrence and progression. J Urol 2002;167:1634-1637.
60. Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer. 1999;86:2102-2108.
61. Cheng L, Zhang S, Ulbright T, Bostwick DG, MacLennan T, Eble J. Genetic analysis of papillary urothelial neoplasm of low malignant potential. Mod Pathol. 2002;15:158A.
62. Fujii Y, Kawakami S, Koga F, Nemoto T, Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int. 2003;92:559-562.
63. Desai S, Lim SD, Jimenez RE, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000;13:1315-1323.
64. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology. 2002;60:315-319.
65. McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol. 2003;16:623-629.
66. Montironi R, Lopez-Beltran A, Mazzuccheli R, Bostwick DG. Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol. 2003;56:91-95.
67. Sauter G, Algaba F, Amin M, et al. Non-invasive urothelial tumours. WHO classification of non-invasive papillary urothelial tumors. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours.
68. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in TA papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol. 2001;165:1124-1130.
69. Herr HW. Tumor progression and survival of patients with high grade, non-invasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000;163:60-61.
70. Wolf H, Melsen F, Pedersen SE, Nielsen KT. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl. 1994;157:147-151.
71. Lamm DL. Carinoma in situ. Urol Clin North Am. 1992;19:499-508.
72. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-866.